8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2011

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

000-33001

(Commission File Number)

Delaware	77-0154833
(State or other jurisdiction of incorporation)	(I.R.S. Employer Identification No.)

1501 Industrial Road

San Carlos, CA 94070

(Address of principal executive offices, with zip code)

650-802-0400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 4, 2011 Natus Medical Incorporated appointed John T. Buhler to the new position of President and Chief Operating Officer. Mr. Buhler is expected to commence his employment with the Company on February 14, 2011. Jim Hawkins, who previously held the title of President and Chief Executive Officer, will continue to serve as CEO and as a member of the Board of Directors.

Mr. Buhler was employed by Avantis Medical Systems as President and Chief Executive officer from January 2011 to February 2011. He held various positions at SenoRx from May 2008 through July 2010, including President and Chief Executive Officer from March 2010 through July 2010, President and Chief Operating Officer from October 2009 to March 2010, Senior Vice President and Chief Commercial Officer from April 2009 to October 2009, Vice President of Global Sales and Business Development from October 2008 until April 2009, and Vice President of International Sales and Business Development from May 2008 until October 2008. From August 2005 to May 2008, Mr. Buhler served as President and Chief Executive Officer at Ultrasonix Medical Corporation, a privately held manufacturer of diagnostic ultrasound imaging equipment. From 1998 to 2005, Mr. Buhler held various positions at General Electric, last serving as Vice President and General Manager of GE’s Ultrasound Performance Technologies Division in Shanghi, China.

Mr. Buhler will receive an annual base salary of $325,000 and receive an equity award of 120,000 options and 60,000 shares of restricted stock that will vest over a four-year period. He will also be eligible for a cash bonus under the same terms as for the other executive officers of the Company as described in the Company’s Current Report on Form 8-K filed with the Commission on December 21, 2010, with a target bonus of 50% of base salary.

A copy of the press release announcing Mr. Buhler’s appointment is attached as exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

Exhibit No.	Description
99.1	Press release dated February 9, 2011 announcing the appointment of John Buhler as President and Chief Operating Officer of the Company and other financial data.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NATUS MEDICAL INCORPORATED
	(Registrant)
Dated: February 9, 2011	By:	/s/ Steven J. Murphy
		Vice President Finance and Chief Financial         Officer

Exhibit Index

Exhibit No.	Description
99.1	Press release dated February 9, 2011 announcing the appointment of John Buhler as President and Chief Operating Officer of the Company and other financial data.

EX-99.1

Exhibit 99.1

Natus Medical Appoints John T. Buhler as President and COO

SAN CARLOS, Calif. (February 9, 2011) – Natus Medical Incorporated (Nasdaq:BABY) today announced the appointment of John T. Buhler as President and Chief Operating Officer of the Company. Over his 28 year career, Mr. Buhler has overseen and directed rapidly growing enterprises both big and small within the medical device industry, recently as President and CEO of SenoRx, Inc. (Nasdaq:SENO) prior to its acquisition in July 2010. His experience includes senior management positions at General Electric, last serving as VP and GM of GE’s $500 million Ultrasound Performance Technologies Division covering China and Asia; President and CEO of Ultrasonix Medical Corp. in Canada; and VP of Operations for Diasonics Inc.

“I am pleased to have John join the Natus management team in the new position of President and Chief Operating Officer,” said Jim Hawkins, Chief Executive Officer of Natus. “During the past six years, our business has grown from $36 million in annual revenue to our current $250 million annual revenue run rate. By bringing in an experienced executive like John to report to me and manage our day-to-day operations, I will be better able to focus on our strategic growth opportunities and accretive acquisitions. This should better enable us to achieve our current goal of reaching $500 million of annual revenue in 2014 and further success thereafter.”

“Natus has achieved tremendous growth and success over the past six years, becoming a leading provider of healthcare products in the markets it serves and with operations on three continents,” said Buhler. “I look forward to joining this successful team and helping to drive Natus to even greater levels of profitability in the years to come.”

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatalogy, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

Additional information about Natus Medical can be found at www.natus.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding the achievement of a $500 million revenue goal in 2014. These statements relate to current estimates and assumptions of our management as of the date of this press release, and future events or Natus’ future financial performance or results, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, and risks associated with bringing new products to market, integrating acquired businesses, and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus’ annual report on Form 10-K for the year ended December 31, 2009, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

COMPANY CONTACT:

Natus Medical Incorporated

Steven J. Murphy

Chief Financial Officer

(650) 802-0400

InvestorRelations@Natus.com